Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Study for ErbB2 Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Junction Adenocarcinoma Treated With Capecitabine Plus Oxaliplatin With or Without Lapatinib
Brief Summary: This is an international multi-center trial that will enroll patients with locally advanced, unresectable, or metastatic gastric, esophageal, or gastro-esophageal junction cancer whose tumors have amplification of the ErbB2 (HER2) gene. The trial will investigate whether lapatinib, when added to the chemotherapy regimen, capecitabine plus oxaliplatin (CapeOx), extends the time to progression and overall survival. Tumor ErbB2 (HER2) status must be known before trial entry. CapeOx is administered to all patients, and patients will be randomly assigned to receive either lapatinib or placebo.


Options:
A: Arm Label: 1- Docetaxel plus Oxaliplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Drug: oxaliplatin | Arm Label: 2- Docetaxel plus oxaliplatin plus cetuximab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Drug: cetuximab, Drug: oxaliplatin | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): 1- Docetaxel plus Oxaliplatin, 2- Docetaxel plus oxaliplatin plus cetuximab | Intervention Type: DRUG; Name: cetuximab; Assigned to Arm(s): 2- Docetaxel plus oxaliplatin plus cetuximab | Intervention Type: DRUG; Name: oxaliplatin; Assigned to Arm(s): 1- Docetaxel plus Oxaliplatin, 2- Docetaxel plus oxaliplatin plus cetuximab
B: Arm Label: TE (Taxotere and Eloxatin); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin | Arm Label: TEF (Taxotere, Eloxatin and 5-FU); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin + 5-FU | Arm Label: TEX (Taxotere, Eloxatin and Xeloda); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin + Capecitabine | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin; Assigned to Arm(s): TE (Taxotere and Eloxatin) | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin + 5-FU; Assigned to Arm(s): TEF (Taxotere, Eloxatin and 5-FU) | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin + Capecitabine; Assigned to Arm(s): TEX (Taxotere, Eloxatin and Xeloda)
C: Arm Label: CapeOx plus Lapatinib; Type: EXPERIMENTAL; Interventions: Drug: Lapatinib, Drug: Capecitabine, Drug: Oxaliplatin | Arm Label: CapeOx plus Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Capecitabine, Drug: Oxaliplatin | Intervention Type: DRUG; Name: Lapatinib; Assigned to Arm(s): CapeOx plus Lapatinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): CapeOx plus Placebo | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): CapeOx plus Lapatinib, CapeOx plus Placebo | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): CapeOx plus Lapatinib, CapeOx plus Placebo
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: S-1/Cisplatin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-FU/cisplatin | Intervention Type: DRUG; Name: S-1/Cisplatin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: 5-FU/cisplatin; Assigned to Arm(s): B

Answer: C